Speakers discuss healthcare innovation cycles, AI applications, and policy impacts on drug pricing and device adoption
Summary
Chris Schott and Robbie Marcus analyze the healthcare sector's current dynamics, highlighting a shift from patent expiration concerns to a robust innovation cycle in pharmaceuticals. They identify key therapeutic breakthroughs in oncology and immunology, while noting the rapid adoption of oral GLP-1 formulations and new pricing structures for seniors. Robbie Marcus contrasts this with MedTech pressures driven by high interest rates and reduced elective procedure volumes. The speakers also evaluate the immediate versus long-term impacts of AI in drug discovery and clinical workflows. Finally, they address policy changes under the Trump administration and the rising influence of Chinese biotech on global partnerships.
Key takeaways
- 1 Schott describes Keytruda as the largest oncology product ever launched but predicts it could be replaced in 5-7 years by better therapies.
Unidentified speaker (speaker_1) · 3:38
Episode sections
- 0:04 – 2:58
Sector Overview and Innovation Cycles
Speakers discuss the healthcare sector's dual role as an AI beneficiary and defensive hedge. Chris Schott notes a pivot from patent expiration concerns to a robust innovation cycle in pharma, while Robbie Marcus highlights current pressures in MedTech due to high interest rates and reduced innovation.
- 2:58 – 4:42
Therapeutic Innovation: Oncology and Immunology
Chris Schott identifies oncology as a key area with breakthroughs in pancreatic and small cell lung cancer via ADCs and bispecifics. He also mentions personalized cancer vaccines (INT) and improvements in immunology treatments for conditions like psoriasis and Crohn's.
- 4:42 – 6:45
Medical Device Adoption Criteria
Robbie Marcus explains that device adoption requires a 'win-win-win' for patients (better outcomes), hospitals (profits), and payers (lower total cost). He cites cardiology, structural heart, and robotics as areas seeing progress, though some new tech may have higher prices with lower system savings.
- 6:45 – 10:25
GLP-1 Market Dynamics and Affordability
Schott describes the GLP-1 market as early-stage with low penetration rates. He highlights the shift to oral formulations, the upcoming retatrutide (triple agonist), and amylin-based drugs for better tolerability. He notes a 20% price drop in 2026 and new access for seniors at $50/month.
- 10:25 – 12:36
AI in Drug Discovery and Development
Schott argues AI's immediate impact is in clinical data analysis and filing acceleration, saving 6-12 months of development time. He views early-stage target discovery as still unproven (3-5 years out), potentially benefiting smaller disease states more than major markets like cancer.
- 12:36 – 15:06
AI in Medical Devices and Clinical Workflows
Marcus notes AI is already used in robotics to stabilize surgeon hands, digital overlays, and medical imaging. He highlights AI-driven insulin dosing and a swallowable camera pill for GI tracking. He predicts AI will soon help ICU staff predict patient deterioration.
- 15:06 – 17:44
Healthcare Policy and Pricing Environment
Schott mentions a deal with the Trump administration for flatter developed market pricing for new drugs. Marcus notes ACA subsidy cuts in 2026 and Medicaid qualification changes in 2027 have led to deceleration in elective procedure volumes like knee care and cataracts.
- 17:44 – 21:12
Macro Resilience and Chinese Biotech
Schott views pharma as defensive and rate-insensitive, expecting M&A acceleration. Marcus anticipates new product introductions in 2027. Schott highlights China's biotech rise from 5% to 50% of new drugs in a decade, creating partnership and competition opportunities.
Claims worth verifying
Healthcare sector is drawing attention as both an AI beneficiary and a defensive hedge against the AI trade.
Alif Korkmaz ·0:04
How to verify: Check J.P. Morgan sector reports or equity research notes from late 2026 discussing healthcare valuation multiples relative to tech. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Chris Schott has covered the pharma group for over 25 years.
Unidentified speaker (speaker_1) ·1:47
How to verify: Verify Chris Schott's tenure at J.P. Morgan via his LinkedIn profile or J.P. Morgan analyst bios. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
MedTech has seen negative revisions across the group for the first time since the global financial crisis.
Unidentified speaker (UNKNOWN) ·2:26
How to verify: Review J.P. Morgan MedTech sector outlook reports from 2026 for consensus earnings revision data. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Pancreatic cancer and small cell lung cancer treatments meaningfully extended life in the last year.
Unidentified speaker (speaker_1) ·3:18
How to verify: Check FDA approvals for oncology drugs in 2026-2026 and associated clinical trial results published in medical journals. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Keytruda is the largest oncology product ever launched.
Unidentified speaker (speaker_1) ·3:38
How to verify: Compare Keytruda's annual sales figures against other oncology drugs using IMS Health or IQVIA market data. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Oral GLP-1 drugs accounted for about 25% of the market by volume in 2026.
Unidentified speaker (speaker_1) ·7:49
How to verify: Check GLP-1 market share reports from IQVIA or similar healthcare data providers for 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Primary sourceRetatrutide targets three incretins.
Unidentified speaker (speaker_1) ·8:09
How to verify: Review clinical trial data or FDA briefing documents for Retatrutide (LY3298176) mechanism of action. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
GLP-1 prices came down about 20% in 2026.
Unidentified speaker (speaker_1) ·8:29
How to verify: Analyze pharmacy benefit manager (PBM) rebate data or average wholesale price (AWP) trends for GLP-1s in 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Primary sourceSeniors gained access to GLP-1s at $50 a month in July 2026.
Unidentified speaker (speaker_1) ·8:49
How to verify: Check CMS announcements or Medicare Part D policy updates regarding GLP-1 coverage caps effective July 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Primary sourceChina's share of new drugs rose from 5% to 50% in a decade.
Unidentified speaker (UNKNOWN) ·19:51
How to verify: Compare FDA/EMA approval statistics for drugs originating from Chinese biotech firms in 2026 vs 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Do your own research
- Verify the 'robust innovation cycle' claim by reviewing recent FDA approvals and clinical trial phase advancements for major pharma companies.
- Check MedTech company earnings calls and order backlog data for signs of volume deceleration due to interest rates.
- Confirm the 25% market share for oral GLP-1 drugs by analyzing sales data from Novo Nordisk, Eli Lilly, and other relevant manufacturers.
- Review the specific clinical trial results for retatrutide to assess its efficacy compared to existing GLP-1 therapies.
- Investigate the Trump administration's pricing policies and their impact on developed market drug pricing structures.
- Analyze Medicaid enrollment data and elective procedure volume statistics to verify the claimed deceleration in knee care and cataract surgeries.
- Assess Chinese biotech companies' pipeline strength and partnership announcements to evaluate the shift in global drug development influence.
Full transcriptexpand
0:04Alif Korkmaz: Healthcare is evolving fast. AI is changing how drugs are discovered and how healthcare is delivered. From the stock market perspective, healthcare sector is drawing a lot of attention, both as a potential AI beneficiary as well as a defensive hedge against the AI trade. There is also a lot of debate on healthcare policy, new medicines, devices, and affordability. In today's episode, we'll break down what what's changing across the industry, what it all means for patients and providers, and what investors should be watching out for next. Welcome to JP Morgan's Making Sense. I'm Alif Korkmaz, U.S. Healthcare Sector Specialist here at JP Morgan. Joining me for today's discussion are Chris Schatz, who leads our U.S. Diversified Biopharma Equity Research, and Robbie Marcus, who leads U.S. Medical Supply. Supplies and Device Equity Research here at JP Morgan. Chris and Robbie, thank you so much for being here today.
0:56Unidentified speaker (speaker_1): Thanks for having us. Thanks
0:57Unidentified speaker (speaker_2): a lot, Alif.
0:58Alif Korkmaz: Chris, let's start with you today. To start the conversation, what are your bigger picture thoughts on fundamentals for the pharma sector? What are investors paying attention to the most?
1:07Unidentified speaker (speaker_1): Sure. And yeah, thanks for having us on today. Uh so pharma for me, it's a uh really a story about an innovation cycle. So my group's always been this kind of balance between new product launches on one hand and patent expirations on the other hand. So basically how much is coming in, what's going away. And for honestly, much of the last decade, the focus has been on the ladder, what's going away. It's been all these patent explorations. I'm actually seeing that focus though really starting to pivot. So what we're seeing now is a pretty significant innovation cycle across the industry. It's across therapeutic areas. It's it's honestly some of the most robust RD innovation we've seen in my career. I've covered the group over 25 years. So I'm thinking that's increasingly going to be the focus of conversation for biotech and pharma investors.
1:52Alif Korkmaz: Wonderful. Robbie, same question for you. What are your big picture thoughts for the med tech sector? Aaron
1:57Unidentified speaker (UNKNOWN): Powell
1:58Unidentified speaker (speaker_2): Medical devices, similar to pharma, pharma's as as we look across much of healthcare, is an innovation. innovation-driven growth sector. However, we're we're at a trough now where the financial conditions around the world, some of the government changes in funding for health care, and just a lack of new innovation over the last 24 months has left MedTech where we've seen negative revisions across the group, where high interest rates are putting pressure on
2:26Unidentified speaker (UNKNOWN): the government.
2:27Unidentified speaker (speaker_2): patients and it's more difficult to pay for co-pays for procedures. So for the first time since the global financial crisis, we're actually seeing a little more pressure on procedure volumes in what's normally historically a a pretty steady, consistent growth sector. So we're looking year into 2027, Then maybe things are bottoming, things are improving, and you know, we're we're hopeful that we could see some more positive results.
2:51Alif Korkmaz: Great. Chris, in biopharma, where is innovation most promising? Um, what unmet patient needs do you think it could address?
2:58Unidentified speaker (speaker_1): Sure, yeah. So as I mentioned, we're kind of this big innovation cycle is kind of a theme for us. Uh it's across a number of areas. Uh the ones I could probably most focus on, I guess first would be oncology. So cancer treatment remains one of the biggest unmet needs in healthcare. And what we're seeing here. is a breakthrough in a number of tumor types. So I think just in the last year, we've had treatments for I want to say two of the most difficult forms of cancer. So it's like pancreatic cancer or small cell lung cancer. These were horrible conditions, but we've got two drugs that meaningfully extend life there. We've got new technologies. So things like ADCs and bi-specifics. What these are doing is improving standard of care and those in bigger tumor types. Lung cancer, for example, this is the largest form of cancer out there. Uh Keytruda, it's the largest oncology product ever launched. We think there's a good chance that that drug gets replaced in the next five or seven years with actually much better therapies. And then finally, and this is one I'm sure a lot of people have seen in the press, we've got a drug called INT. Uh the first use of this is in skin cancer. Uh, but effectively here, uh companies are creating personalized vaccines to help prevent cancer recurrence. So it's a lot of kind of interesting themes playing out all at once. Elsewhere, immunology, that's like the second largest therapeutic area in biopharma. We have conditions like psoriasis,
4:18Crohn's disease, asthma. Industry is developing combination therapies, oral therapies. So basically it's going to make drugs that are better options for patients in terms of. more convenient, that products that work better should expand the market. And then finally, I'm sure we'll touch upon this later on, but the GLP ones and obesity remains kind of a core theme for our sector, and we're still seeing a pretty healthy new product cycle coming down the pipeline there as well.
4:41Alif Korkmaz: Absolutely.
4:42Unidentified speaker (UNKNOWN): And
4:42Alif Korkmaz: Robbie, when you think about meaningful progress in medical devices, what do you think matters the most? Is it better outcomes for patients, easier access? lower costs, or is it something else? And kind of using that to measure, which areas are you seeing the most progress happening?
4:58Unidentified speaker (speaker_2): Alif, I'm gonna cheat a little bit here. And it's really all three, right? There's three key stakeholders when you're looking at the medical device sector. There's the payers. The payers give a fixed reimbursement per procedure to the hospitals. The hospitals then negotiate process. pricing with the manufacturers. The patients obviously at the end benefit the most from better outcomes. So if you can have products that help patients more than older products that generate cost savings for the hospitals and lower prices for the payers, it's a win-win-win Win-win for everyone. And quite frankly, that's what we've been seeing throughout the past 15 years. after the global financial crisis and a big negative downturn in the medical device sector. And they shifted their focus towards better outcomes, lower prices, and better profits for the hospital. So it's really all of the above.
5:53Unidentified speaker (UNKNOWN): If
5:54Unidentified speaker (speaker_2): you think about where you're seeing this the most, well, the ones you highlighted: cardiology, diabetes, robotics, particularly within cardiology. structural heart, think of that as heart valve replacement, as well as electrophysiology and new forms of ablation technology where we're seeing that become much safer and faster, but at higher prices, so better profits, but lower savings to the system. So th those are really the areas and and it it's all of the above.
6:25Alif Korkmaz: Absolutely. Thank you. Chris, turning to you, you alluded to GLP1s as being a big area. And it's interesting that we recorded a similar podcast three years ago and absolutely came a big long way in terms of the innovation that we've seen in the GLP1 space. But as we're seeing expansion and use and these products are becoming more affordable, can you walk us through what are the latest developments in the space in terms of both product innovation as well as the patient accessibility?
6:50Unidentified speaker (speaker_1): It's an interesting dynamic. We feel like I'm a GLP one analyst instead of a drug analyst sometimes here. But it's and it's it feels like it's been forever this category has been around. But if you take a step back, I mean these are fairly new drugs. So we're talking about penetration rates that are high single digits in the US, more like 2% internationally. So I think we're pretty early in this journey of what GLP ones will do to the broader market. When I look at developments from here, it's really on two fronts. So one is we're gonna have better drugs. And and to me the answer is definitively yes. We've got a number of these that are on the horizon. We've had phase three data, talk about those in a second. The second and and probably more importantly, is affordability. So these are these are not like your typical drug category where people get broad access. These are a lot of patients are still paying out of pocket. Price is absolutely uh a hurdle for for adoption. And I think we're also seeing some some developments in that front as well. So let's maybe talk about the new product front side. So in 2026, we saw oral GLP1. So we moved these things away from injections to pills. That's already about 25% of the market by volume. So it's been having pretty rapid uptake. Next up, what we're seeing is actually more effective medications. So this drug called retitrucide. retrucide, All you need to know about that drug, it targets three increotins. incratins instead of the one or two that have been targeted initially. It's going to translate to faster weight loss, higher weight loss. Definitively,
8:09in our view, could become a best-in-class product. And then finally, we've got another innovation called amylen, and these drugs are more tolerable. So that's one of the main problems with these drugs, is that they have GI problems, these amylins don't. So when I kind of look at that kind of, you know, one launch last year, another launch coming in 27, another launch coming in 2028, 2029. standard of care gets better.
8:28Unidentified speaker (UNKNOWN): On
8:29Unidentified speaker (speaker_1): the price side, as I mentioned before, affordability is a problem. Price came down about 20% in 2026. I think we could see honestly double-digit annual price erosion 27 and beyond. Uh we're also getting things like seniors. Uh, seniors didn't have access to these drugs historically. They can now get these at $50 a month. That happened in July this year. We've already seen over a million seniors. go on this medication in in just a couple months. So I I think when we kind of combine this mix of affordability and innovation, this is space where we continue to see a ton of growth ahead.
9:01Alif Korkmaz: Awesome. And Robbie, from your perspective, as we get new devices and procedures, what determines better day move from promising new technologies to becoming routine care?
9:11Unidentified speaker (speaker_2): Yeah. Good question. I'm going to lean a little bit on the last. answer, where it has to be better outcomes for patients, better profits for the hospital, and better outcomes for the payers as well, meaning less total cost. So if you have a device that is really inexpensive, makes the hospital a ton of money, but it's at worse outcomes for the patients than something else, at least in developed markets, we're not seeing that product work. well adopted. If you have something that has great outcomes, but is just unprofitable for the hospital to administer to patients based on the existing reimbursement rates, that also won't get well adopted. So it's finding something in the sweet spot where you have strong outcomes for patients. The hospitals can at least not lose money on it, and the more money they can make, obviously, the better. And then for the payers, it also has to be a reasonable amount that doesn't prohibit them from paying for it. So if you can check all three of those boxes, we're seeing it, that's really what drives it. But it it's obviously patients first. So the outcomes are the most important. And then secondarily is the profits for the system.
10:24Alif Korkmaz: Great.
10:25Unidentified speaker (UNKNOWN): So
10:25Alif Korkmaz: we open opened up the conversation. today by talking about AI and how AI is really evolving really fast and changing how drugs are developed and how care is being delivered. Chris, I want to turn back to you here. Where do you think AI is really beginning to make a practical difference in drug discovery and development?
10:42Unidentified speaker (UNKNOWN): And
10:43Alif Korkmaz: what do you think still needs to be proven?
10:45Unidentified speaker (speaker_1): I feel like we get all this AI uh kind of conversation around drug development as like one of these like poster post-child child kind of industries. I I get it on one hand, it's it's a very data intensive industry. There's clearly some use case for AI here, it's just you know whether it's data analysis, filing, applications, et cetera. I do think the actual impact, though, is a bit more nuanced and will vary. So where will there be the biggest impact? So you think about research and development, that's actually like two separate things. There's developing a drug and actually a kind of coming up with the actual molecule on the development side. So think about things like human clinical studies. We're already seeing a benefit here. You can analyze clinical data faster, you can pull together filings to get drugs to market sooner.
11:29Unidentified speaker (UNKNOWN): It
11:29Unidentified speaker (speaker_1): might sound like the boring stuff, but I've got an industry where patent protection only lasts 15 to 18 years. And if I can carve six or 12 twelve months off a development cycle, is real value being created for the industry. And that that's happening today. I think the other piece of this, so the early stage research, so the actual making the drug and finding the right target, I think that's still a bit of an unknown. So is this going to be incremental development? Absolutely. Is it transformational? I think it's too early to make that call yet. Um and I think it's gonna going to be probably three to five years till we have a better idea. So what we could see here, smaller diseases that got less attention historically, AI may just give those disease states way more resource than they ever had. At the same time, I think about some of those bigger markets, I just mentioned cancer, GLP1s, where there already has been tons of effort, research, focus. This might end up being a little bit less of a benefit there. So again, uh TBD, I'd say on that PC. piece of it. Aaron
12:27Unidentified speaker (UNKNOWN): Powell
12:27Alif Korkmaz: Absolutely. And Robbie, turning to you here, how do you think about AI and digital tools improving medical device use, patient monitoring, or clinical workflows?
12:36Unidentified speaker (UNKNOWN): Aaron Powell
12:37Unidentified speaker (speaker_2): I mean, it's already in a lot of products around and you know places you probably wouldn't think about. The good news at least uh for clinicians and and healthcare providers is I think we're probably even more than three to five years away from having a robot do a surgery single-handedly without the intervention of a human. But robotics right now already uses AI tremendously to eliminate shaking of the hands of the surgeon. Next steps, you can see digital overlays. Think of having the best surgeons in the world with you while you're doing the procedure, automatic suturing for really complex situations. We're already seeing that and very close on the horizon within robotics. Medical imaging, it's been there for years, and it's already enhancing and improving medical imaging to help radiologists pick up on slight nuances that the human eye wouldn't be able to discern. on its own. Diabetes, all of the insulin pumps and the continuous glucose monitors feed into the cloud where AI is already helping improve the algorithms and the treatment
13:52regimens and dosing of insulin, and that's only going to continue to improve as we strive for an artificial pancreas that eliminates all human interaction and replacing the pancreas. for type 1 and type 2 insulin using patients. And I think there's also some really interesting innovations that maybe don't get as much focus. One of the companies has a pill you can swallow, and it will go through the entire gastrointestinal track and use AI based on cameras in this microscope. microscopic or tiny little pill to replace the need for scopes inside of you. So it's already there. I think it's all only going to grow. And I I would say one more area where we see the biggest potential is to help with nursing staff in intensive care units, on the floors in the hospital, setting up cameras. to see if a patient is showing symptoms or signs of some impending illness or bad event coming before anyone could pick up on it. So that there's ways that it's just only going to improve outcomes and treatment in hospitals.
15:06Alif Korkmaz: Great. Very interesting. So coming out of midterms elections, there's obviously a lot of discussion around policy and what it means from now on. Let's talk about how U.S. policy pricing and reimbursement changes are shaping how healthcare organizations are making decisions. So Chris, let's start with you on your thoughts on this.
15:23Unidentified speaker (speaker_1): Sure. When I think about policy and pricing is the big unknown for for biopharma. And I think in particular, this kind of topic around what the US pays versus what everyone else in the world pays. So on that front, we actually did a deal the industry struck with the Trump administration about a year ago. where the sector, I kind of described this as a kind of like ease its way into flatter developed market pricing. So it was kind of grandfathering in legacy products, the industry committing to new products, coming at more of a globally flat price point. I think that's going to be that was viewed as a great outcome for the the industry and it kind of alleviating what's long been this overhang of and topic of debate for the sector. I think that's going to be something we're watching going forward. So probably unlikely that changes with a new Congress.
16:09Unidentified speaker (UNKNOWN): I
16:09Unidentified speaker (speaker_1): think the debate becomes with a new administration coming in 2028, 2029. Does this become an area of focus again for the sector? So that's probably the specific topic I'm spending my most time on right
16:19Unidentified speaker (UNKNOWN): now.
16:20Unidentified speaker (speaker_2): For medical devices, it's less about pricing, it's more about insurance coverage and with the affordable. Care Act, we saw a significant uplift of millions of patients who were previously uninsured, gaining insurance coverage, and introduced in the budget bill last year, started with cuts to the Affordable Care Act subsidies in 2026 and more difficult qualifications for Medicaid starting in 2027. So combined with higher interest rates and inflation and out-of-pocket pay, along with less reimbursement on the Affordable Care Act subsidies in 2026, we've seen for the first time in many, many years deceleration in procedure volume growth in some of the more elective procedures like knee care, contact lens,
17:14Unidentified speaker (UNKNOWN): per
17:14Unidentified speaker (speaker_2): purchases, intraocular lenses for cataracts, which is all cash pay.
17:21Unidentified speaker (UNKNOWN): And
17:21Unidentified speaker (speaker_2): next year we'll also be expecting Medicaid to see some some more declines in covered patients. So we'll see how how that stabilizes next year. Like Chris said, you know, we're not expecting any material changes with the the new um election, but with the new administration in 2020 2028, there could be more changes to improve coverage.
17:44Alif Korkmaz: Chris, let me turn to you here. In a higher interest rate environment, how well do you think the pharma sector is positioned to better some of these macro pressures? How the interest rates might affect the sector's resilience and deal-making outlook from here? Aaron
17:56Unidentified speaker (UNKNOWN): Powell
17:56Unidentified speaker (speaker_1): Sure. So I, I mean, as we talked about before, fundamentals of the sector seem like they're in a good place. And I have I a sector that's quite that, on honestly, isn't super economically sensitive, isn't rate sensitive. It's a pretty defensive sector, especially when you have the fundamentals going the right direction. I think this is going to create a fairly healthy MA environment for the group.
18:17Unidentified speaker (UNKNOWN): Um
18:17Unidentified speaker (speaker_1): and you kind of think of these companies, they're all developing new products, they do have some remaining patent expirations.
18:23Unidentified speaker (UNKNOWN): This
18:23Unidentified speaker (speaker_1): innovation isn't just contained to my company's company, it's the whole industry. So if we start to see some of these SMID cap companies that maybe are a bit more macro exposed, a bit more interest rate exposed, you could have an environment where it just makes more sense to partner or acquire some of these assets. So I think we're probably in a world where these bolt-on type acquisitions we've seen from the pharma industry the last couple of years, I would think of anything could accelerate as we go through the next few years as both those pipelines get de-risked, and then if we're in this macro. environment where that just maybe makes more sense than it would have historically.
19:01Alif Korkmaz: Let's start with you, Robbie.
19:03Unidentified speaker (UNKNOWN): Yeah,
19:03Unidentified speaker (speaker_2): look, I I think in medical devices, we said it earlier, it's an innovation-driven Driven growth sector. And while 2025 and 2026 didn't have a significant amount of new product introductions or data catalysts, which usually comes in the form of large trial presentations at medical meetings, there are a number across most of my coverage universe and medical devices in 2027. So I think really what we're going to be looking for is lots of new product introductions and and how they're received, as well as a lot of groundbreaking science throughout
19:39Unidentified speaker (UNKNOWN): the
19:39Unidentified speaker (speaker_2): entire year at medical meetings.
19:42Unidentified speaker (speaker_3): Chris, how about you?
19:43Unidentified speaker (speaker_1): Yeah, in and I guess one theme we haven't talked about that I'm spending a lot of time on is the rise of the Chinese biotech industry. So if you look at China,
19:51Unidentified speaker (UNKNOWN): if
19:51Unidentified speaker (speaker_1): you looked a decade ago, maybe five or ten percent of new drugs came out of China. We're looking at that number pushing towards 50% today. So going basically from 5% to 50 in a decade is pretty stunning. I think this is going to change the way the industry operates on a number of fronts. This is going to be faster innovation, which is great for patients. It's going to create a lot more partnership opportunities for my larger cap companies to develop these drugs globally. It's going to be competition for everybody. So for me, I think it's going to be really interesting to see both how both the industry as well as policymakers kind of adapt to this kind of new ecosystem that's that's starting to emerge.
20:28Alif Korkmaz: All right. I think that's a good place for us to wrap up. Robbie, Chris, thank you so much for participating today. Really appreciate your insights. Thanks
20:35Unidentified speaker (speaker_2): for having us, Olivia.
20:36Unidentified speaker (speaker_1): Thank you.
20:36Unidentified speaker (speaker_3): Of course. Thanks for listening to JP Morgan's Making Sense. If you've enjoyed this conversation, share your feedback by leaving a comment or review wherever you listen to podcasts. And be sure to follow our channel so you don't miss an episode. This communication is provided for information purposes only. Please visit www.jpm.com forward slash research forward slash disclosures for important disclosures. Copyright 2026 JPMorgan Chase ⁇ Co. All rights reserved.